TSHA
Taysha Gene Therapies, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 85 | +6 | 146.63M | $997.83M | +12 | −5 |
| Q1 2026 | 81 | -9 | 130.93M | $584.01M | +4 | −14 |
| Q4 2025 | 90 | 0 | 135.71M | $746.41M | +2 | −1 |
| Q3 2025 | 18 | -1 | 108.64M | $355.25M | — | −1 |
| Q2 2025 | 16 | +5 | 65.80M | $152.01M | +5 | — |
| Q1 2025 | 8 | -4 | 14.26M | $19.83M | +1 | −5 |
| Q4 2024 | 12 | +5 | 19.11M | $33.06M | +5 | — |
| Q3 2024 | 6 | 0 | 7.50M | $15.08M | +2 | −2 |
| Q2 2024 | 6 | — | 5.37M | $12.04M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 6.47M | — | $11.20M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 5.00M | New | $8.65M | 0.0% | New | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.57M | +0.3% | $6.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.57M | +0.3% | $6.18M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 1.46M | New | $2.53M | 0.0% | New | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 878.45K | New | $1.52M | 0.0% | New | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 745.21K | -73.9% | $1.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 585.59K | +26.4% | $1.01M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 585.59K | +26.4% | $1.01M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Millennium Management ✦ | 151.61K | New | $262,292 | 0.0% | New | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 138.11K | -71.6% | $238,932 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Marshall Wace ✦ | 138.11K | -71.6% | $238,932 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 65.33K | +9.4% | $114,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 25.35K | -63.5% | $43,863 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 25.35K | -63.5% | $43,863 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 12.30K | New | $21,279 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $8.65M | 0.0% |
| Norges Bank | $2.53M | 0.0% |
| Renaissance Technologies | $1.52M | 0.0% |
| Millennium Management | $262,292 | 0.0% |
| Two Sigma Investments | $21,279 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 190 holders, 265.00M shares, $1.21B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.